Thymoglobulin Injectable Product
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hematological Malignancy
Conditions
Hematological Malignancy
Trial Timeline
Mar 31, 2024 → Mar 31, 2026
NCT ID
NCT06066255About Thymoglobulin Injectable Product
Thymoglobulin Injectable Product is a phase 2 stage product being developed by Sanofi for Hematological Malignancy. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06066255. Target conditions include Hematological Malignancy.
What happened to similar drugs?
0 of 1 similar drugs in Hematological Malignancy were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06066255 | Phase 2 | Recruiting |
Competing Products
20 competing products in Hematological Malignancy